成都圣诺生物科技股份有限公司 关于持股5%以上股东权益变动至5%以下并触及1%刻度的提示性公告

Core Viewpoint - The announcement details a significant reduction in shareholding by a major shareholder, Sichuan Development Securities Investment Fund Management Co., Ltd., which has decreased its stake in Chengdu Sanno Biological Technology Co., Ltd. from 7.0000% to 4.9999%, thus falling below the 5% threshold for major shareholders [2][3][11]. Group 1: Shareholder Information - The shareholder involved in the reduction is Sichuan Development Securities Investment Fund Management Co., Ltd., representing the Sichuan Capital Market Relief Development Securities Investment Fund Partnership (Limited Partnership) [2]. - There are no concerted actions with other shareholders in this reduction [2]. Group 2: Details of the Equity Change - The reduction occurred between September 18, 2025, and December 10, 2025, with a total of 3,147,896 shares sold, accounting for 2.0001% of the company's total share capital [2]. - Following this transaction, the number of shares held by the shareholder decreased from 11,016,995 shares to 7,869,099 shares [2][11]. Group 3: Impact and Future Plans - This equity change does not trigger a mandatory tender offer and will not result in a change of control or significant impact on the company's governance structure or ongoing operations [3]. - The shareholder's reduction plan is part of a previously disclosed strategy due to funding needs, with a potential for further reductions not exceeding 4,721,578 shares (3% of total share capital) within the next 12 months [9].